276 related articles for article (PubMed ID: 28467878)
1. The Failure of Solanezumab - How the FDA Saved Taxpayers Billions.
Sacks CA; Avorn J; Kesselheim AS
N Engl J Med; 2017 May; 376(18):1706-1708. PubMed ID: 28467878
[No Abstract] [Full Text] [Related]
2. [Not Available].
Watt JA; Marple R; Hemmelgarn B; Straus SE
CMAJ; 2021 Nov; 193(43):E1680-E1682. PubMed ID: 34725122
[No Abstract] [Full Text] [Related]
3. The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point.
Eiser AR
Am J Med; 2021 Dec; 134(12):1442-1443. PubMed ID: 34256026
[No Abstract] [Full Text] [Related]
4. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
Alexander GC; Emerson S; Kesselheim AS
JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
[No Abstract] [Full Text] [Related]
5. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA.
Karlawish J; Grill JD
Nat Rev Neurol; 2021 Sep; 17(9):523-524. PubMed ID: 34267383
[No Abstract] [Full Text] [Related]
6. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Schulman KA; Greicius MD; Richman B
JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
[No Abstract] [Full Text] [Related]
7. Controversial Approval of New Drug to Treat Alzheimer's Disease.
Aschenbrenner DS
Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
[TBL] [Abstract][Full Text] [Related]
8. US FDA defends approval of Alzheimer's disease drug.
Jaffe S
Lancet; 2021 Jul; 398(10294):12. PubMed ID: 34217382
[No Abstract] [Full Text] [Related]
9. FDA Drug Approval and the Ethics of Desperation.
Largent EA; Peterson A; Lynch HF
JAMA Intern Med; 2021 Dec; 181(12):1555-1556. PubMed ID: 34694325
[No Abstract] [Full Text] [Related]
10. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
Zissimopoulos J; Jacobson M; Chen Y; Borson S
JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058
[TBL] [Abstract][Full Text] [Related]
11. Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
Gleason A; Ayton S; Bush AI
Med J Aust; 2022 Mar; 216(4):172-174. PubMed ID: 35141902
[No Abstract] [Full Text] [Related]
12. A contentious FDA ruling for Alzheimer's disease.
The Lancet Neurology
Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273
[No Abstract] [Full Text] [Related]
13. Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
Rubin R
JAMA; 2021 Aug; 326(6):469-472. PubMed ID: 34287610
[No Abstract] [Full Text] [Related]
14. Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made?
Kurkinen M; Tran L
J Alzheimers Dis; 2021; 84(3):969-971. PubMed ID: 34657888
[No Abstract] [Full Text] [Related]
15. Landmark Alzheimer's drug approval confounds research community.
Mullard A
Nature; 2021 Jun; 594(7863):309-310. PubMed ID: 34103732
[No Abstract] [Full Text] [Related]
16. Revisiting FDA Approval of Aducanumab.
Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
[No Abstract] [Full Text] [Related]
17. Alzheimer Drug Lecanemab Gains Traditional FDA Approval.
Harris E
JAMA; 2023 Aug; 330(6):495. PubMed ID: 37466999
[No Abstract] [Full Text] [Related]
18. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
Manly JJ; Glymour MM
JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
[No Abstract] [Full Text] [Related]
19. FDA approves new drug to treat dementia.
J Gerontol Nurs; 2015 Mar; 41(3):5. PubMed ID: 25710261
[No Abstract] [Full Text] [Related]
20. Donanemab: FDA experts recommend approval of Alzheimer's drug.
Dyer O
BMJ; 2024 Jun; 385():q1327. PubMed ID: 38876494
[No Abstract] [Full Text] [Related]
[Next] [New Search]
